OPKO Health Inc
NASDAQ:OPK

Watchlist Manager
OPKO Health Inc Logo
OPKO Health Inc
NASDAQ:OPK
Watchlist
Price: 1.505 USD -2.27%
Market Cap: 1B USD
Have any thoughts about
OPKO Health Inc?
Write Note

OPKO Health Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

OPKO Health Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
OPKO Health Inc
NASDAQ:OPK
Long-Term Debt
$432.3m
CAGR 3-Years
32%
CAGR 5-Years
10%
CAGR 10-Years
20%
Abbvie Inc
NYSE:ABBV
Long-Term Debt
$58.5B
CAGR 3-Years
-8%
CAGR 5-Years
12%
CAGR 10-Years
15%
Gilead Sciences Inc
NASDAQ:GILD
Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Long-Term Debt
$56.9B
CAGR 3-Years
20%
CAGR 5-Years
15%
CAGR 10-Years
6%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Long-Term Debt
$114m
CAGR 3-Years
-39%
CAGR 5-Years
-27%
CAGR 10-Years
-18%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Long-Term Debt
$2.7B
CAGR 3-Years
11%
CAGR 5-Years
31%
CAGR 10-Years
17%
No Stocks Found

OPKO Health Inc
Glance View

Market Cap
1B USD
Industry
Biotechnology

In the bustling world of healthcare and biotechnology, OPKO Health Inc. stands as a unique and dynamic player. Founded by the ambitious mind of Dr. Phillip Frost, the company has woven itself into the fabric of diverse biomedical sectors. OPKO predicates its enterprise on the integration of complementary businesses ranging from diagnostics to pharmaceuticals, creating synergies that are not just theoretical, but markedly operational. At the heart of its operations lies the interplay between new drug discovery and diagnostics development, allowing OPKO to leverage cutting-edge technologies in crafting novel health solutions. By honing in on significant medical unmet needs, they aspire to deliver innovations that address chronic diseases such as diabetes, oncology, and neurological disorders. This strategic weaving together of distinct healthcare sectors manifests in OPKO's sprawling portfolio—from the renowned Rayaldee, which targets secondary hyperparathyroidism, to its advanced diagnostics segments, which include proprietary tests for specific cancers and other conditions. The company's revenue streams can be best visualized as an interlocking lattice of healthcare services and products. It earns through a blend of product sales, licensing, and collaborative agreements with other biotech and pharmaceutical giants. Rayaldee, as a potent testament to their R&D prowess, contributes robustly to their revenue, while the diagnostics division, powered by their substantial investment in technology and infrastructure, brings in consistent sales from various testing services. The company’s BioReference Laboratories, one of the largest full-service diagnostic laboratories in the U.S., also plays a critical role in their financial architecture, offering both routine and esoteric tests. Additionally, OPKO is involved in strategic collaborations and licensing arrangements, enhancing its market footprint and creating channels for revenue infusion through partnerships with industry leaders. Ultimately, OPKO Health Inc.'s narrative is one of leveraging diversified capabilities and strategic partnerships to carve out a formidable presence in the complex landscape of global healthcare.

OPK Intrinsic Value
1.764 USD
Undervaluation 15%
Intrinsic Value
Price

See Also

What is OPKO Health Inc's Long-Term Debt?
Long-Term Debt
432.3m USD

Based on the financial report for Sep 30, 2024, OPKO Health Inc's Long-Term Debt amounts to 432.3m USD.

What is OPKO Health Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
20%

Over the last year, the Long-Term Debt growth was 89%. The average annual Long-Term Debt growth rates for OPKO Health Inc have been 32% over the past three years , 10% over the past five years , and 20% over the past ten years .

Back to Top